Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.

Immunome, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

BOTHELL, WASH.--(BUSINESS WIRE)--IMMUNOME, INC. (THE COMPANY) (NASDAQ: IMNM), A BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING FIRST-IN-CLASS AND BEST-IN-CLASS TARGETED CANCER THERAPIES, ANNOUNCED TODAY THAT ON AUG. 1, 2025, THE COMPENSATION COMMITTEE OF THE COMPANY'S BOARD OF DIRECTORS (THE COMPENSATION COMMITTEE) GRANTED INDUCEMENT AWARDS CONSISTING OF NON-STATUTORY STOCK OPTIONS TO PURCHASE AN AGGREGATE OF 39,000 SHARES OF COMMON STOCK TO 5 NEW EMPLOYEES UNDER THE COMPANY'S 2024 INDUCEMENT.

IMMUNOME REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

BOTHELL, WASH.--(BUSINESS WIRE)--IMMUNOME, INC. (THE COMPANY) (NASDAQ: IMNM), A BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING FIRST-IN-CLASS AND BEST-IN-CLASS TARGETED CANCER THERAPIES, ANNOUNCED TODAY THAT ON JULY 1, 2025, THE COMPENSATION COMMITTEE OF THE COMPANY'S BOARD OF DIRECTORS (THE COMPENSATION COMMITTEE) GRANTED INDUCEMENT AWARDS CONSISTING OF NON-STATUTORY STOCK OPTIONS TO PURCHASE AN AGGREGATE OF 125,500 SHARES OF COMMON STOCK TO 8 NEW EMPLOYEES UNDER THE COMPANY'S 2024 INDUCEMENT.

BOTHELL, WASH.--(BUSINESS WIRE)--IMMUNOME, INC. (THE COMPANY) (NASDAQ: IMNM), A BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING FIRST-IN-CLASS AND BEST-IN-CLASS TARGETED CANCER THERAPIES, ANNOUNCED TODAY THAT ON JUNE 2, 2025, THE COMPENSATION COMMITTEE OF THE COMPANY'S BOARD OF DIRECTORS (THE COMPENSATION COMMITTEE) GRANTED INDUCEMENT AWARDS CONSISTING OF NON-STATUTORY STOCK OPTIONS TO PURCHASE AN AGGREGATE OF 173,000 SHARES OF COMMON STOCK TO 13 NEW EMPLOYEES UNDER THE COMPANY'S 2024 INDUCEMEN.

BOTHELL, WASH.--(BUSINESS WIRE)--IMMUNOME TO PRESENT AT UPCOMING INVESTOR CONFERENCES.

IMMUNOME TO PRESENT AT UPCOMING INVESTOR CONFERENCES

BOTHELL, WASH.--(BUSINESS WIRE)--IMMUNOME, INC. (THE COMPANY) (NASDAQ: IMNM), A BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING FIRST-IN-CLASS AND BEST-IN-CLASS TARGETED CANCER THERAPIES, ANNOUNCED TODAY THAT ON MAY 1, 2025, THE COMPENSATION COMMITTEE OF THE COMPANY'S BOARD OF DIRECTORS (THE COMPENSATION COMMITTEE) GRANTED INDUCEMENT AWARDS CONSISTING OF NON-STATUTORY STOCK OPTIONS TO PURCHASE AN AGGREGATE OF 164,500 SHARES OF COMMON STOCK TO NINE NEW EMPLOYEES UNDER THE COMPANY'S 2024 INDUCEME.

BOTHELL, WASH.--(BUSINESS WIRE)--IMMUNOME, INC. (NASDAQ: IMNM), A BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING FIRST-IN-CLASS AND BEST-IN-CLASS TARGETED CANCER THERAPIES, TODAY ANNOUNCED THAT IMMUNOME MANAGEMENT WILL PARTICIPATE IN A FIRESIDE CHAT AT THE 24TH ANNUAL NEEDHAM VIRTUAL HEALTHCARE CONFERENCE ON THURSDAY, APRIL 10, 2025 AT 12:45 P.M. EASTERN TIME. INTERESTED PARTIES CAN ACCESS THE LIVE AUDIO WEBCAST FOR THIS CONFERENCE FROM THE INVESTOR RELATIONS SECTION OF THE COMPANY'S WEBSITE AT WW.

IMMUNOME TO PRESENT AT THE 24TH ANNUAL NEEDHAM VIRTUAL HEALTHCARE CONFERENCE

BOTHELL, WASH.--(BUSINESS WIRE)--IMMUNOME, INC. (THE COMPANY) (NASDAQ: IMNM), A BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING FIRST-IN-CLASS AND BEST-IN-CLASS TARGETED CANCER THERAPIES, ANNOUNCED TODAY THAT ON APRIL 1, 2025, THE COMPENSATION COMMITTEE OF THE COMPANY'S BOARD OF DIRECTORS (THE COMPENSATION COMMITTEE) GRANTED INDUCEMENT AWARDS CONSISTING OF NON-STATUTORY STOCK OPTIONS TO PURCHASE AN AGGREGATE OF 228,000 SHARES OF COMMON STOCK TO FIVE NEW EMPLOYEES UNDER THE COMPANY'S 2024 INDUCE.

BOTHELL, WASH.--(BUSINESS WIRE)--IMMUNOME, INC. (NASDAQ: IMNM), A BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING FIRST-IN-CLASS AND BEST-IN-CLASS TARGETED CANCER THERAPIES, TODAY ANNOUNCED FINANCIAL RESULTS FOR THE FULL YEAR ENDED DECEMBER 31, 2024 AND PROVIDED A BUSINESS UPDATE. IMMUNOME'S EFFICIENT EXECUTION IN 2024 LAID THE FOUNDATION FOR A PRODUCTIVE 2025, SAID CLAY B. SIEGALL, PH.D., PRESIDENT AND CHIEF EXECUTIVE OFFICER. WE ARE PLEASED WITH THE PROGRESS OF OUR PIPELINE AND, WITH MULTIPLE.

IMMUNOME REPORTS FULL YEAR 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BOTHELL, WASH.--(BUSINESS WIRE)--IMMUNOME, INC. (NASDAQ: IMNM), A BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING FIRST-IN-CLASS AND BEST-IN-CLASS TARGETED CANCER THERAPIES, TODAY ANNOUNCED THAT THE FIRST PATIENT HAS BEEN DOSED IN THE PHASE 1, FIRST-IN-HUMAN TRIAL OF IM-1021, A ROR1-TARGETED ADC. IMMUNOME IS DEVELOPING DIFFERENTIATED ADCS THAT WE BELIEVE CAN GREATLY BENEFIT CANCER PATIENTS, SAID BOB LECHLEIDER, M.D., CHIEF MEDICAL OFFICER AT IMMUNOME. THE DOSING OF OUR FIRST PATIENT WITH IM-1021.

IMMUNOME DOSES FIRST PATIENT IN PHASE 1 TRIAL OF IM-1021, A ROR1-TARGETED ADC

BOTHELL, WASH.--(BUSINESS WIRE)--IMMUNOME, INC. (THE COMPANY) (NASDAQ: IMNM), A BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING FIRST-IN-CLASS AND BEST-IN-CLASS TARGETED CANCER THERAPIES, ANNOUNCED TODAY THAT ON MARCH 3, 2025, THE COMPENSATION COMMITTEE OF THE COMPANY'S BOARD OF DIRECTORS (THE COMPENSATION COMMITTEE) GRANTED INDUCEMENT AWARDS CONSISTING OF NON-STATUTORY STOCK OPTIONS TO PURCHASE AN AGGREGATE OF 49,000 SHARES OF COMMON STOCK TO FOUR NEW EMPLOYEES UNDER THE COMPANY'S 2024 INDUCEM.

Immunome, Inc.

IMNM

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Immunome, Inc.

IMNM.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

IMNM